{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:03:05Z","timestamp":1766138585907,"version":"3.40.5"},"reference-count":62,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Since the late 2000s, Europe has granted approval for various thrombotic risk\u2010related uses of direct oral anticoagulants (DOACs). Unlike traditional anticoagulants, DOACs do not necessitate routine coagulation monitoring. Nevertheless, clinical practice often encounters bleeding events associated with these medications, making the need for effective reversal strategies evident.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The study aims to take stock of current reversal strategies for DOACs, with a particular emphasis on the latest compounds that have been developed or are currently under development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For obtaining information regarding the ongoing reversal strategies and the compounds under development, we referred to ClinicalTrials website, PubMed, and Google Scholar.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 2024, two specific antidotes to DOACs have already received approval when reversal of anticoagulation is needed owing to life\u2010threatening or uncontrolled bleeding: idarucizumab that reverses the effects of dabigatran, and andexanet alfa, designed to counteract activated factor X inhibitors such as apixaban and rivaroxaban. Furthermore, ciraparantag, a potential universal reversal agent, is currently in advanced stages of clinical development. Concerns remain regarding the safety of specific reversal agents, especially concerning the risk of thrombosis. Additionally, the cost of these antidotes remains high. Consequently, nonspecific strategies to counteract anticoagulant medications, including activated charcoal, hemodialysis, and concentrates of coagulation factors, still have utility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>With the validation of specific and nonspecific antidotes, DOACs could supplant traditional oral anticoagulants. This progress represents a significant advancement in anticoagulation therapy. However, ongoing research is crucial to address remaining safety concerns of the specific reversion agents of DOACs in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/fcp.12992","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:18:51Z","timestamp":1707869931000},"page":"674-684","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Latest advances in the reversal strategies for direct oral anticoagulants"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-418X","authenticated-orcid":false,"given":"Jean","family":"Escal","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Laboratory, INSERM, SAINBIOSE U1059 Saint\u2010\u00c9tienne University Hospital, Jean Monnet University  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Lanoisel\u00e9e","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Saint\u2010\u00c9tienne University Hospital  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Poenou","sequence":"additional","affiliation":[{"name":"Innovation and Pharmacology Clinical Research Unit, INSERM, SAINBIOSE U1059 Saint\u2010\u00c9tienne University Hospital, Jean Monnet University  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Zufferey","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Saint\u2010\u00c9tienne University Hospital  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvy","family":"Laporte","sequence":"additional","affiliation":[{"name":"Innovation and Pharmacology Clinical Research Unit, INSERM, SAINBIOSE U1059 Saint\u2010\u00c9tienne University Hospital, Jean Monnet University  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[{"name":"Vascular and Therapeutic Medicine Department, INSERM, SAINBIOSE U1059 Saint\u2010\u00c9tienne University Hospital, Jean Monnet University Saint\u2010\u00c9tienne  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Laboratory, INSERM, SAINBIOSE U1059 Saint\u2010\u00c9tienne University Hospital, Jean Monnet University  Saint\u2010Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_9_2_1","DOI":"10.4103\/0019\u20105049.144643"},{"doi-asserted-by":"publisher","key":"e_1_2_9_3_1","DOI":"10.5811\/westjem.2014.12.22933"},{"doi-asserted-by":"publisher","key":"e_1_2_9_4_1","DOI":"10.3390\/cells11203214"},{"doi-asserted-by":"publisher","key":"e_1_2_9_5_1","DOI":"10.3174\/ajnr.A3000"},{"doi-asserted-by":"publisher","key":"e_1_2_9_6_1","DOI":"10.1161\/CIRCRESAHA.112.276741"},{"doi-asserted-by":"publisher","key":"e_1_2_9_7_1","DOI":"10.1016\/j.amjmed.2017.02.048"},{"doi-asserted-by":"publisher","key":"e_1_2_9_8_1","DOI":"10.1016\/j.bmcl.2009.02.111"},{"unstructured":"European medicine agency.Eliquis2021. [online]. Available athttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis","key":"e_1_2_9_9_1"},{"unstructured":"European medicine agency.Pradaxa2021. [online]. Available athttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pradaxa","key":"e_1_2_9_10_1"},{"unstructured":"European medicine agency.Lixiana. 2021. [online]. Available athttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lixiana","key":"e_1_2_9_11_1"},{"unstructured":"European medicine agency.Xarelto (rivaroxaban): An overview of Xarelto and why it is authorised in the EU. 2021. [online]. Available athttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto","key":"e_1_2_9_12_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_13_1","DOI":"10.1016\/j.jaccao.2022.10.014"},{"doi-asserted-by":"publisher","key":"e_1_2_9_14_1","DOI":"10.3390\/ijerph19031436"},{"doi-asserted-by":"publisher","key":"e_1_2_9_15_1","DOI":"10.3389\/fcvm.2022.907197"},{"doi-asserted-by":"publisher","key":"e_1_2_9_16_1","DOI":"10.15420\/ecr.2017:11:2"},{"doi-asserted-by":"publisher","key":"e_1_2_9_17_1","DOI":"10.3390\/ijms22168531"},{"doi-asserted-by":"publisher","key":"e_1_2_9_18_1","DOI":"10.1161\/CIRCULATIONAHA.119.041687"},{"unstructured":"European medicine agency.Praxbind: summary of product characteristics. 2015. [online]. Available athttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/praxbind","key":"e_1_2_9_19_1"},{"unstructured":"European medicine agency.Ondexxya. 2016. [online]. Available athttps:\/\/www.ema.Europa.eu\/en\/medicines\/human\/EPAR\/ondexxya","key":"e_1_2_9_20_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_21_1","DOI":"10.1161\/CIRCULATIONAHA.116.021831"},{"doi-asserted-by":"publisher","key":"e_1_2_9_22_1","DOI":"10.5837\/bjc.2022.001"},{"doi-asserted-by":"publisher","key":"e_1_2_9_23_1","DOI":"10.1056\/NEJMoa1707278"},{"doi-asserted-by":"publisher","key":"e_1_2_9_24_1","DOI":"10.4103\/1793\u20105482.165795"},{"doi-asserted-by":"publisher","key":"e_1_2_9_25_1","DOI":"10.1160\/TH14\u201012\u20101080"},{"doi-asserted-by":"publisher","key":"e_1_2_9_26_1","DOI":"10.1055\/s\u20100039\u20101695771"},{"doi-asserted-by":"publisher","key":"e_1_2_9_27_1","DOI":"10.1056\/NEJMoa1510991"},{"doi-asserted-by":"publisher","key":"e_1_2_9_28_1","DOI":"10.2147\/JBM.S121550"},{"issue":"9","key":"e_1_2_9_29_1","first-page":"530","article-title":"Andexanet alfa (Andexxa\u00ae) for the reversal of direct oral anticoagulants","volume":"44","author":"Momin JH","year":"2019","journal-title":"Pt"},{"doi-asserted-by":"publisher","key":"e_1_2_9_30_1","DOI":"10.1161\/atvb.33.suppl_1.A10"},{"doi-asserted-by":"publisher","key":"e_1_2_9_31_1","DOI":"10.1182\/bloodadvances.2017007112"},{"doi-asserted-by":"publisher","key":"e_1_2_9_32_1","DOI":"10.1182\/blood.V122.21.3636.3636"},{"doi-asserted-by":"publisher","key":"e_1_2_9_33_1","DOI":"10.1182\/blood.v124.21.4269.4269"},{"doi-asserted-by":"publisher","key":"e_1_2_9_34_1","DOI":"10.1160\/TH16\u201003\u20100224"},{"doi-asserted-by":"publisher","key":"e_1_2_9_35_1","DOI":"10.1056\/NEJMoa1814051"},{"unstructured":"ClinicalTrials.gov.Trial of andexanet alfa in ICrH patients receiving an oral FXa inhibitor. [online]. Available athttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03661528","key":"e_1_2_9_36_1"},{"issue":"21","key":"e_1_2_9_37_1","article-title":"Small molecule antidote for anticoagulants","volume":"126","author":"Laulicht B","year":"2012","journal-title":"Circulation"},{"doi-asserted-by":"publisher","key":"e_1_2_9_38_1","DOI":"10.1182\/blood.2020007116"},{"doi-asserted-by":"publisher","key":"e_1_2_9_39_1","DOI":"10.1093\/eurheartj\/ehab637"},{"doi-asserted-by":"publisher","key":"e_1_2_9_40_1","DOI":"10.1016\/j.thromres.2016.07.008"},{"unstructured":"ClinicalTrials.gov.Study of ciraparantag for reversal of anticoagulation induced by edoxaban apixaban or rivaroxaban in healthy adults. [online]. Available athttps:\/\/clinicaltrials.gov\/study\/NCT04593784","key":"e_1_2_9_41_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_42_1","DOI":"10.1007\/s13181\u2010012\u20100276\u20105"},{"doi-asserted-by":"publisher","key":"e_1_2_9_43_1","DOI":"10.1007\/s40256\u2010013\u20100055\u2010y"},{"doi-asserted-by":"publisher","key":"e_1_2_9_44_1","DOI":"10.1007\/s40262\u2010016\u20100485\u20101"},{"doi-asserted-by":"publisher","key":"e_1_2_9_45_1","DOI":"10.1124\/dmd.112.050575"},{"doi-asserted-by":"publisher","key":"e_1_2_9_46_1","DOI":"10.1124\/dmd.112.050260"},{"doi-asserted-by":"publisher","key":"e_1_2_9_47_1","DOI":"10.1177\/0091270009351883"},{"doi-asserted-by":"publisher","key":"e_1_2_9_48_1","DOI":"10.1160\/TH12\u201008\u20100573"},{"doi-asserted-by":"publisher","key":"e_1_2_9_49_1","DOI":"10.1007\/s40262\u2010013\u20100049\u20106"},{"doi-asserted-by":"publisher","key":"e_1_2_9_50_1","DOI":"10.1016\/j.jmv.2015.02.004"},{"doi-asserted-by":"publisher","key":"e_1_2_9_51_1","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"doi-asserted-by":"publisher","key":"e_1_2_9_52_1","DOI":"10.1093\/europace\/euv309"},{"doi-asserted-by":"publisher","key":"e_1_2_9_53_1","DOI":"10.1097\/ALN.0000000000001631"},{"doi-asserted-by":"publisher","key":"e_1_2_9_54_1","DOI":"10.1016\/j.jacc.2021.04.061"},{"doi-asserted-by":"publisher","key":"e_1_2_9_55_1","DOI":"10.1160\/TH12\u201003\u20100179"},{"doi-asserted-by":"publisher","key":"e_1_2_9_56_1","DOI":"10.1056\/NEJMoa1006221"},{"doi-asserted-by":"publisher","key":"e_1_2_9_57_1","DOI":"10.1111\/tme.12212"},{"doi-asserted-by":"publisher","key":"e_1_2_9_58_1","DOI":"10.1016\/j.xphs.2017.03.035"},{"doi-asserted-by":"publisher","key":"e_1_2_9_59_1","DOI":"10.1111\/jth.13673"},{"doi-asserted-by":"publisher","key":"e_1_2_9_60_1","DOI":"10.1161\/STROKEAHA.120.029789"},{"doi-asserted-by":"publisher","key":"e_1_2_9_61_1","DOI":"10.1038\/nm.4149"},{"doi-asserted-by":"publisher","key":"e_1_2_9_62_1","DOI":"10.1038\/s41467\u2010017\u201000647\u20109"},{"doi-asserted-by":"publisher","key":"e_1_2_9_63_1","DOI":"10.1055\/s\u20100038\u20101667014"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T09:25:06Z","timestamp":1721208306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/fcp.12992"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12992","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"type":"print","value":"0767-3981"},{"type":"electronic","value":"1472-8206"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"2023-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}